Betahistine-Vertex, tablets 24 mg 60 pcs

A synthetic analog of histamine. It is an agonist of H1-receptors of inner ear vessels and an antagonist of H3-receptors of vestibular nuclei of CNS. By direct agonist effect on H1-receptors of the inner ear vessels, as well as indirectly through the effect on H3-receptors it improves microcirculation and capillary permeability, normalizes the endolymph pressure in the labyrinth and cochlea, increases blood flow in the basilar artery.

It has a pronounced central effect, being an inhibitor of H3-receptor nuclei of the vestibular nerve. It improves conduction in neurons of vestibular nuclei at brainstem level.

The clinical manifestation of the above properties is reduction of the frequency and intensity of dizziness, reduction of tinnitus, improvement of hearing if it is reduced.

Pharmacokinetics

absorption and distribution

Absorbed rapidly. Cmax is reached after 3 h. The binding to plasma proteins is low.

Elimation

It is almost completely excreted in the urine as a metabolite (2-pyridylacetic acid) within 24 hours. T1/2 is 3-4 hours.

Indications

syndromes including dizziness and headache, tinnitus, progressive hearing loss, nausea and vomiting;
treatment and prevention of vestibular vertigo of various origins;
Meniere’s disease or syndrome.

Pharmacological effect

Synthetic analogue of histamine. It is an agonist of H1 receptors in the vessels of the inner ear and an antagonist of H3 receptors in the vestibular nuclei of the central nervous system. Through a direct agonistic effect on H1 receptors of the vessels of the inner ear, as well as indirectly through an effect on H3 receptors, it improves microcirculation and capillary permeability, normalizes endolymph pressure in the labyrinth and cochlea, and increases blood flow in the basilar artery.

It has a pronounced central effect, being an inhibitor of H3 receptors in the nuclei of the vestibular nerve. Improves conductivity in neurons of the vestibular nuclei at the level of the brain stem.

The clinical manifestation of these properties is a decrease in the frequency and intensity of dizziness, a decrease in tinnitus, and an improvement in hearing if it is reduced.

Pharmacokinetics

Suction and distribution

Absorbed quickly. Cmax is reached after 3 hours. Plasma protein binding is low.

Removal

Almost completely excreted in the urine in the form of a metabolite (2-pyridylacetic acid) within 24 hours. T1/2 – 3-4 hours.

Special instructions

Patients with a history of gastric or duodenal ulcers, pheochromocytoma or bronchial asthma should be prescribed the drug under regular medical supervision.

Impact on the ability to drive vehicles and operate machinery

Betahistine does not have a sedative effect and does not affect the ability to drive a car or engage in activities that require rapid psychomotor reactions.

Active ingredient

Betahistine

Composition

Pills

Active ingredient:

betahistine dihydrochloride 24 mg;

Excipients:

MCC;

lactose (milk sugar);

citric acid monohydrate;

colloidal silicon dioxide (Aerosil);

crospovidone;

talc;

magnesium stearate.

Contraindications

– lactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome;

– children under 18 years of age (due to lack of data);

— pregnancy (due to lack of data);

— lactation period (due to lack of data);

– hypersensitivity to any of the components of the drug.

The drug should be prescribed with caution in case of gastric or duodenal ulcer (history), pheochromocytoma, bronchial asthma.

Side Effects

Gastrointestinal disorders, allergic reactions of the skin (skin rash, itching, urticaria), Quincke’s edema.

Overdose

Symptoms: nausea, vomiting, convulsions.

Treatment: gastric lavage, taking activated carbon, symptomatic therapy.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C.

Shelf life

2 years

Manufacturer

Vertex, Russia